Before you start using Onapgo, tell your healthcare provider about all of your medical conditions, including: difficulty staying awake during the daytime • dizziness, fainting spells, or low blood pressure • asthma; allergies to any medicines containing sulfites • heart problems • a history of stroke or other brain problems;

2 days ago · Onapgo’s approval was based on data from an European placebo-controlled Phase 3 study (NCT02006121) called TOLEDO that indicated continuous apomorphine infusions reduced off time and increased on time, when symptoms are adequately controlled, among patients who were experiencing multiple hours of daily off time with levodopa-based treatment ...

1 day ago · During the Phase 3 study, ONAPGO significantly reduced the amount of daily OFF time at 12 weeks from baseline (p=0.0114), with ONAPGO-treated patients (n=53) experiencing a 2.6-hour reduction ...

1 day ago · Onapgo is a wearable pump designed to provide a continuous subcutaneous infusion of Supernus’ apomorphine (Apokyn). The drug is meant to allow patients more control over their daily "off" time ...

1 day ago · ONAPGO is the first and only subcutaneous apomorphine infusion device designed to deliver continuous treatment throughout the waking day, providing consistent control of OFF time, which is a ...

Because Onapgo is delivered continuously through an under-the-skin infusion, the medication bypasses the gastrointestinal track and directly enters the brain, stimulating dopamine receptors — potentially leading to more predictable symptom improvement. Researchers evaluated Onapgo in the Phase III TOLEDO clinical trial.

1 day ago · Onapgo, a subcutaneous apomorphine infusion device, is approved for advanced Parkinson's disease, offering continuous symptom management without surgery. The TOLEDO trial showed apomorphine ...

21 hours ago · In trial, Onapgo – formerly known as SPN-830 – significantly reduced these daily off episodes by an average of 2.47 hours, compared to the placebo treatment (0.58 hours).

1 day ago · The treatment branded Onapgo will be available in the U.S. in the second quarter. The drug regulator's greenlight brings an end in the company's years-long effort to market the pump-based ...

16 hours ago · Onapgo, which is expected to be available in the second quarter of 2025, is a wearable subcutaneous infusion device that provides continuous treatment with the dopamine agonist apomorphine to help reduce ‘off’ time. Because Onapgo is delivered subcutaneously, the drug bypasses the gastrointestinal tract and directly enters the brain ...